Business Wire

“Trophées des Cartes innovantes 2017”: IDEMIA and CB Awarded for the F.CODE Biometric Payment Card

Jaa

At the Trophées des cartes innovantes 2017 card innovation awards, e-money and payment professionals awarded the trophy for most innovative technology in the “Security - Identity - Authentication” category for the F.CODE Comfort biometric payment card to IDEMIA, the global leader in trusted identities for an increasingly digital world, and Groupement des Cartes Bancaires CB.

This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171220005685/en/

(Photo: Business Wire)

(Photo: Business Wire)

As the number of contactless card payments continues to grow1, IDEMIA devised F.CODE Comfort, the card that uses biometric fingerprints to identify its holder, thus opening the way to raising the limit on contactless payments currently set at €30 per transaction on the French market.

F.CODE Comfort is equipped with an integrated digital fingerprint reader providing instant authentication of the cardholder on each contactless payment. This cutting-edge technology, thoroughly tested in the Lab by CB, received the accolade of e-money and payment professionals at the industry’s annual card innovation awards, the Trophées des cartes innovantes.

Above all else, IDEMIA’s F.CODE Comfort card guarantees payment security for users, alleviating potential consumer fears regarding contactless payment: the authentication generated by the biometric fingerprint frees cardholders to carry out transactions with no other payment limit than that on the card itself. The system itself is really simple to use and encourages cardholders to make more frequent use of this fast, secure and eminently practical means of payment.

Because the payment solution is so closely linked to its holder, whose identity is authenticated with every transaction, it offers the added advantage of restricting still further the opportunities for fraud.

“It is a great honour to have been awarded the ‘Security – Identification – Authentication’ trophy for our F.CODE card, as a mark of recognition from sector professionals. This innovative payment solution, which we have tested in partnership with CB, speaks directly to our mission, which is to empower consumers in an increasingly digital world to pay, identify themselves and communicate with optimum security but, above all, with the maximum simplicity,” said Eric Duforest, Executive Vice-President of Financial Institutions activities at IDEMIA.

Philippe Lalaunie, CB CEO, added: “This new-generation card is designed to extend contactless payment to higher payment thresholds thanks to biometric authentication. It is currently being trialled via LAB by CB and we are working in particular on the smoothest, but also the most secure, fingerprint enrolment process possible.”

About IDEMIA

OT-Morpho is now IDEMIA, the global leader in trusted identities for an increasingly digital world. Through Augmented Identity, we empower citizens and consumers alike to interact, pay, connect, travel and vote in ways that are now possible in a connected environment. With close to $3bn in revenues, IDEMIA serves clients in 180 countries.

About CB

CB, innovation inside

Created in 1984 to implement a universal and interoperable card payment system and a system for cash withdrawals from Automated Teller Machines (ATMs), Groupement des Cartes Bancaires CB, a non-profit organisation, is the governance body of the CB card payment system. In 2016, CB numbered 112 member banks and payment institutions throughout the world.

CB is the leading payment system in France, with:

  • 66.5 million CB cards in circulation,
  • 57,136 ATMs,
  • 1,490,144 CB merchant contracts
  • 12.11 billion transactions, totalling €592.5 billion in 2016.

For further information, visit www.cartes-bancaires.com

1 Since January 2017, the number of contactless CB transactions hit 1 billion on 16 November 2017 (source: www.cartes-bancaires.com)

Contact information

Media
Idemia:
Hanna Sebbah, T +33(0)6-63-73-30-30
hanna.sebbah@havas.com
or
Manon Gaudefroy, T +33(0)6-85-30-60-02
manon.gaudefroy@havas.com
or
CB:
Françoise Fanari, T +33(0)1-40-15-58-57
francoise-fanari@cartes-bancaires.com
or
Priscilla Patruno, T +33(0)1-40-15-58-54
priscilla-patruno@cartes-bancaires.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Manchester United and True Religion Launch Denim Range19.10.2018 20:37Tiedote

Manchester United (NYSE:MANU) and luxury denim brand True Religion have collaborated to launch a range of premium club branded denim wear. A first for the club, the new global partnership with the iconic American denim brand will see a range of men’s & women’s co-branded styles go on sale beginning 26th October in the club’s Megastore as well as online via United Direct and truereligion.com & eu.truereligion.com. The exclusive collection features jeans, shirts and jackets, including a highly desirable limited edition denim jacket embroidered with the club’s crest. Fans will have the opportunity to win a selection of clothing from the new range by visiting www.manutd.com/truereligion. Manchester United’s Group Managing Director, Richard Arnold, comments: “True Religion is a well-known, established name in fashion, creating unique designs without compromising on quality. The range we have collaborated on includes the same attention to detail and craftsmanship that has made True Religion

Arch Insurance Announces Strategic Leadership Changes19.10.2018 16:10Tiedote

Arch Insurance today announced that Matt Shulman will assume the newly created role of CEO, Arch Insurance North America, effective January 1, 2019. In this role, he will lead Arch Insurance’s operations in the United States and Canada. He will report to Nicolas Papadopoulo, Chairman and CEO of Arch Worldwide Insurance Group. Mr. Shulman, who has more than 20 years of experience in the insurance industry, has been with Arch Insurance since 2009 and has served as the President and CEO of Arch Insurance Europe since 2016. “Matt brings significant U.S. and international experience to this role. Under his leadership, together with our senior team, Arch Insurance will continue to enhance our value proposition to our customers through a robust, diversified product portfolio, creative solutions and excellent service,” Mr. Papadopoulo said. Arch Insurance has also created a new organizational structure with three Chief Underwriting Officers (CUO) dedicated to specific lines of business. These

Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer19.10.2018 15:00Tiedote

Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that intracranial efficacy data from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1 st Line) trial showed improved intracranial progression-free survival (PFS) and intracranial objective response rate (ORR) with ALUNBRIG (brigatinib) compared to crizotinib among anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) patients. Data for these secondary endpoints will be presented in a poster discussion at the European Society for Medical Oncology (ESMO) 2018 Congress on Friday, October 19 at 2:00 p.m. CET in Munich, Germany. These results further support ALUNBRIG as a potential treatment for adults with ALK+ locally advanced or metastatic NSCLC who had not received a prior ALK inhibitor. ALUNBRIG is currently not approved as first-line therapy for advanced ALK+ NSCLC. “ALK+ NSCLC often spreads to the brain, so having options that can clearly demonstrate efficacy both in the brain an

Vertex Receives European CHMP Positive Opinion for KALYDECO® (ivacaftor) to Treat Patients With Cystic Fibrosis Aged 12 to <24 months With Certain Mutations in the CFTR Gene19.10.2018 14:54Tiedote

Vertex Pharmaceuticals (Europe) Limited today announces that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for KALYDECO® (ivacaftor) to include the treatment of people with cystic fibrosis (CF) aged 12 to <24 months who have at least one of the following nine mutations in their cystic fibrosis transmembrane conductance regulator (CFTR) gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. If the European Commission issues a favorable adoption of the EMA CHMP opinion for the extension of indication, ivacaftor will be the first and only medicine approved in Europe to treat the underlying cause of CF in patients aged 12 to <24 months, who have specific mutations in the CFTR gene. “Cystic fibrosis is a chronic, progressive disease that is present at birth, with symptoms often occurring in infancy, so early treatment is crucial to deliver the best possible outcomes for patients,” said Reshma Kewalr

Tradeshift Announces Q3 2018 Results19.10.2018 14:00Tiedote

Tradeshift, the leader in supply chain payments and marketplaces, today announced results from the third quarter of 2018, marking the tenth quarter in a row of successive growth and beating targets. Tradeshift’s third quarter growth stats announced today include: YoY revenue grew 400 percent (trailing 12 months) YoY new bookings grew 284 percent YoY gross merchandise volume (GMV) grew 262 percent New total contract value grew by $47M in Q3 Tradeshift’s customer roster continued strong growth this quarter adding 27 new customers, including Hertz, Shiseido, ECU, and Fortune 500 leaders in retail apparel, agriculture, engineering and construction, hospitality, travel and food delivery. Tradeshift also expanded its app ecosystem by adding a key partnership with Coface, a global credit insurer. Coface has announced a new app solution on the Tradeshift platform offering risk and business information services to help businesses make decisions by ensuring greater financial transparency between

Schlumberger Announces Third-Quarter 2018 Results19.10.2018 14:00Tiedote

Schlumberger Limited (NYSE: SLB) today reported results for the third quarter of 2018. (Stated in millions, except per share amounts) Three Months Ended Change Sept. 30, 2018 Jun. 30, 2018 Sept. 30, 2017 Sequential Year-on-year Revenue $8,504 $8,303 $7,905 2% 8% Pretax operating income $1,152 $1,094 $1,059 5% 9% Pretax operating margin 13.5% 13.2% 13.4% 36 bps 15 bps Net income - GAAP basis $644 $430 $545 50% 18% Net income, excluding charges & credits* $644 $594 $581 8% 11% Diluted EPS - GAAP basis $0.46 $0.31 $0.39 48% 18% Diluted EPS, excluding charges & credits* $0.46 $0.43 $0.42 7% 10% North America revenue $3,189 $3,139 $2,602 2% 23% International revenue $5,215 $5,065 $5,147 3% 1% North America revenue, excluding Cameron $2,572 $2,546 $2,086 1% 23% International revenue, excluding Cameron $4,559 $4,387 $4,430 4% 3% *These are non-GAAP financial measures. See section below entitled "Charges & Credits" for details. Schlumberger Chairman and CEO Paal Kibsgaard commented, “Our third

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme